PDGFRbeta and HIF-1alpha inhibition with imatinib and radioimmunotherapy of experimental prostate cancer.
The clinical application of radioimmunotherapy (RIT) as a single modality in the treatment of prostate cancer is held back because of poor tumor responses to RIT and unacceptable normal tissue toxicities. The purpose of reported here studies was to develop a multimodality approach to RIT of prostate cancer that includes imatinib, a potent PDGFRbeta inhibitor, and in the course of these studies to define the mechanism of imatinib effects on RIT. Hypothesized interactions between these two modalities depend on the reduction of tumor interstitial fluid pressure with the subsequent increase of (131)ICC49 uptake into the tumor, and the inhibition of HIF-1alpha resulting in the improved tumor radiosensitivity. Levels of HIF-1alpha, IGF-1, PDGF-BB, phospho-PDGFRbeta and VEGF in response to imatinib were examined in PC-3 human prostate adenocarcinoma cells in vitro and in xenografts. RIT was based on (131)ICC49 and it was augmented with imatinib. Although PDGFRbeta appears to be functional in PC-3 tumors, the effect of imatinib on the tumor interstitial fluid pressure was insignificant. PC-3 cells and PC-3 xenografts express constitutive HIF-1alpha, which was significantly inhibited by imatinib. Reduced levels of HIF-1alpha were accompanied by the notable suppression of IGF-1. Simultaneously the increase in tumor levels of mouse and human PDGF-BB was observed. Improved PC-3 responses to RIT+imatinib treatment were significant and lasted approximately two weeks. Tumor doubling times in mice treated with (131)ICC49+imatinib were 21.6 +/- 0.7 days compared to 17.2 +/- 0.5 days in (131)ICC49+PBS-treated control mice. Imatinib alone had no effect on the tumor growth. In conclusion, imatinib inhibits HIF-1alpha expression in PC-3 tumors and improves RIT, but it has no effect on VEGF indicating absence of anti-angiogenic effects. There is a significant time- and dose-dependent reduction in the expression of IGF-1 suggesting an alternative pathway of imatinib-regulated HIF-1alpha expression leading to the improved PC-3 responses to RIT.
Kimura
Yu
Y
Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Inoue
Kotaro
K
Abe
Michio
M
Nearman
Jessica
J
Baranowska-Kortylewicz
Janina
J
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D000077214:Becaplermin; D001549:Benzamides; D045744:Cell Line, Tumor; D004305:Dose-Response Relationship, Drug; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000032:analysis / Q000037:antagonists & inhibitors*; D000068877:Imatinib Mesylate; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008297:Male; D051379:Mice; D008819:Mice, Nude; D010879:Piperazines / Q000627:therapeutic use*; D010982:Platelet-Derived Growth Factor / Q000032:analysis; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy*; D020574:Proto-Oncogene Proteins c-sis; D011743:Pyrimidines / Q000627:therapeutic use*; D016499:Radioimmunotherapy; D020797:Receptor, Platelet-Derived Growth Factor beta / Q000032:analysis / Q000037:antagonists & inhibitors*
D000970:Antineoplastic Agents; D001549:Benzamides; C497443:Hif1a protein, mouse; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D010879:Piperazines; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D011743:Pyrimidines; D000077214:Becaplermin; D007334:Insulin-Like Growth Factor I; D000068877:Imatinib Mesylate; D020797:Receptor, Platelet-Derived Growth Factor beta